In this medfyle

Recent approvals of teclistamab, elranatamab and talquetamab by health authorities highlight the significant efficacy of TCEs in the treatment of MM, particularly for patients with heavily treated relapsed or refractory disease. Despite their promising clinical outcomes, challenges remain in optimizing their use. The effectiveness and safety of these novel agents are reviewed and strategies to enhance their therapeutic potential in MM are explored in a review article.